Skip to main content
Premium Trial:

Request an Annual Quote

Atugen Pens Gene Validation Deal with OGS

NEW YORK, Dec. 11 - Atugen of Berlin said Tuesday it had signed a deal to validate gene targets for Oxford GlycoSciences.

Under the terms of the deal, OGS of Oxford, UK, will provide targets to Atugen, which will validate them using its animal models.

Atugen has developed a technology called GeneBloc, which is designed to block protein production, enabling the company to determine gene function.

The deal marks Atugen's fifth collaboration deal this year. The company’s custormers include Astra Zeneca, Axys Pharmaceuticals, Bayer, Roche BioScience, and Boehringer Ingelheim.

Financial terms of the deal with OGS were not disclosed.

The Scan

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.

US Survey Data Suggests Ancestry Testing Leads Way in Awareness, Use of Genetic Testing Awareness

Although roughly three-quarters of surveyed individuals in a Genetics in Medicine study reported awareness of genetic testing, use of such tests was lower and varied with income, ancestry, and disease history.

Coral Genome Leads to Alternative Amino Acid Pathway Found in Other Non-Model Animals

An alternative cysteine biosynthesis pathway unearthed in the Acropora loripes genome subsequently turned up in sequences from non-mammalian, -nematode, or -arthropod animals, researchers report in Science Advances.

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.